PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all p

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office (USPTO) on November 12, 2024. This patent, titled "Delivery of Agents Using Metastable Liposomes," covers key technological innovations that enable the targeted delivery of therapeutic agents using liposome-based vehicles. The patent's claims cover Lipella's method of using metastable liposomes to deliver th

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company's certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current tra

PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipella Presentation - 2024 Spartan Capital Investor Conference Date: Monday, November 4th, 2024 Time: 9:25 am EST Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference. About Lipella PharmaceuticalsLipella is a clinical-s

Patent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapyAllowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprieta

PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024 Time: 10:30am Webcast: https://m-vest.com/events/healthcare-10152024 Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference. About Lipella PharmaceuticalsLipell

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC). Lipella Pharmaceuticals, a clinical-stage biotechnology company, is focused on addressing serious urological conditions with significant unmet needs. Hemorrhagic cystitis, a painful and potentially life-threat

PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with encouraging findings: The treatment was well tolerated and had no unpleasant taste. Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, commented, "Oral Lichen Planus is a highly disrupti

PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella") will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright's conference is for qualified investors, and Lipella will be giving a virtual presentation and management will be available for one-on-one meetings onsite. For more information and/or to register for the Global Investment Conference, please visit: HCW Events H.C. Wainwright's 26th Annual Global Investment Conference: Date: September 9 through 11, 2024Location: Lotte New York Palace HotelWebc

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study information is now available PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth. Characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores, OLP impacts approximately 6 million Ame

4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

PRE 14A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

DEF 14A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll

Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter sales and issued guidance. Ericsson reported a second-quarter loss of 31 cents per share, compared to year-ago earnings of 7 cents per share. The company reported quarterly sales of $5.59 billion which beat the analyst consensus estimate of $5.36 billion, according to data from Benzinga Pro. Ericsson shares jumped 4.3% to $6.66 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Sentage Holdings Inc. (NASDAQ:SNTG) rose 85.6% to $4.27 in pre-market trading after gaining around 5% on

Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million. Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million. Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million. Qilian Intl Hldg Gr

Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. Lipella's Chief Medical Officer, Dr. Michael Chancellor, stated, "We can now proceed with the confidence that our Phase 2b study design can successfully meet its regulatory objectives. This clarity significantly advances our value proposition."

The Dow Jones index closed higher by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Sabre The Trade: Sabre Corporation (NASDAQ:SABR) Executive Vice President Roshan Mendis bought a total of 31,067 shares at an average price of $3.15. To acquire these shares, it cost around $97,802. What's Happening: On May 2, Sabre reporte

Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings. Natera posted GAAP loss of 56 cents per share, compared to market expectations for a loss of 71 cents per share. The company's quarterly sales came in at $367.700 million versus estimates of $316.306 million. Natera, shares jumped 15.3% to $110.25 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Novavax, Inc. (NASDAQ:NVAX) gained 165% to $11.84 in pre-market trading after the company reported first-quarter results. AEye, Inc. (NASDAQ:LIDR) gained 38.1% to $1.63 in pre-market trading after the company disclosed a par

Maxim Group analyst Jason McCarthy initiates coverage on Lipella Pharmaceuticals (NASDAQ:LIPO) with a Buy rating and announces Price Target of $2.

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella's abstract, "Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity" will be published at www.asco.org/abstracts. Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, "ASCO's 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of